Virtual Library
Start Your Search
B. Yoldas
Author of
-
+
P1.08 - Poster Session with Presenters Present (ID 460)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Surgery
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.08-070 - Salvage Lung Surgery: Difficulties and Results (ID 5447)
14:30 - 14:30 | Author(s): B. Yoldas
- Abstract
Background:
Thoracic surgeons often encounter lung resections following neoadjuvan treatments. Despite that, sometimes patients have curative chemo or/and radiotherapy treatments according to being inoperable for different reasons at the time of diagnosis. After these treatments due to residual tumour or relapses, surgery might be performed and this kind of surgery is called “salvage surgery”. This surgery has more difficulties and complications because of the adverse effects of definitive therapies. In this study we retrospectively analysed such patients undergone salvage surgery, and looked for an answer if we have to avoid or not?
Methods:
Patients operated after curative chemo or/and radiotherapy (4 cycles and more chemotherapy and 66 Gy radiotherapy is accepted as curative radiotherapy) between January 2010 and December 2014 were included in this study and analysed retrospectively. Demographic data, surgical management, morbidity, mortality and survival results were collected.
Results:
Having the described criteria 69 cases (62 male, 7 female) were included in the study. Six of the cases had chemotherapy, 8 radiotherapy only and remaining 55 had only chemotherapy (4-12 cycles). At the postoperative period, 5 cases were undergone rethoracotomy, 10 had prelonged air leakage and were externed with “Heimlich Valve” system, 5 had intraoperative vascular injury; 1 chylothorax, 4 secretion retantion requiring bronchoscopy, and 2 (2.3%) mortality occured. The mean follow up time was 27.6±20.5, ranging with 0.1-69.7 months. Five year survival was calculated as 51.9%.
Conclusion:
Complications after resective surgery following curative treatments are at acceptable rates. Besides this, the 51.9% five year survival rate seems like a last chance for such patients who have had their definitive treatment.
